Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

J. P. Morgan Healthcare Conference

Jean-Paul Clozel, M.D.,
CEO of Actelion, presented at the 
J. P. Morgan Healthcare Conference
on Tuesday, 10 January 2012.
 

Journalist latest news
Investor webcast

Jean-Paul Clozel, M.D.,
CEO of Actelion, presented at the 
J. P. Morgan Healthcare Conference
on Tuesday, 10 January 2012.
 

Journalist latest news
Investor webcast

Global Actelion

Worldmap imageWorldmap image

Actelion has subsidaries in 29 countries, covering all major pharmaceutical markets worldwide

Explore our operations
 

Latest news

09 Jan 2012Actelion to present at the 30th Annual J.P. Morgan Healthcare Conference - Getting ready for Actelion's next growth phase
13 Dec 2011Actelion provides an update on the strategic agreement with Trophos S.A.
30 Nov 2011Professor Dr. Peter Gruss, President of the Max Planck Society, nominated to Actelion's Board
21 Nov 2011Judgment in litigation between Actelion and Asahi Kasei is issued by Californian Court - Original jury verdict reduced by almost USD 170 million - Actelion set to appeal the entire verdict
View all news

Share price

ATLN SIX Swiss Exchange

At 17:30:55 CET 06/02/2012
CHF 36,42Up Down image
+0,05 (+0,14%)
Further stock information